`To:
`Cc:
`
`Subject:
`Date:
`Attachments:
`
`Fishman, Deborah
`Hawthorne, Eric W.; lgreen@geminilaw.com; raynimrod@quinnemanuel.com; Trials
`ychu@wsgr.com; Caine, David A.; Denuyl, David; Ho, Alice; matthewtraupman@quinnemanuel.com;
`landonsmith@quinnemanuel.com
`RE: IPR20223-00532, -00533, and -00566 (note corrected number)
`Wednesday, March 1, 2023 9:41:36 PM
`image001.png
`
`CAUTION: This email has originated from a source outside of USPTO. PLEASE CONSIDER THE SOURCE before
`responding, clicking on links, or opening attachments.
`
`Dear Eric,
`
`Thank you for your inquiry. Patent Owner intends to waive POPR in IPR2023-00532 and IPR2023-
`00533 filed by Petitioner Celltrion, Inc.
`
`However, in IPR2023-00566, filed by Samsung Bioepis, Patent Owner is still considering what it will
`do and is scheduled to meet and confer with counsel for Samsung Bioepis later this week. Once
`Patent Owner makes a decision, it will advise the Board promptly.
`
`With best regards,
`Deborah
`
`_______________
`Deborah Fishman
`Partner | Bio
`
`3000 El Camino Real | Suite 500
`Palo Alto, CA 94306-2112
`T: +1 650.319.4773 | F: +1 650.319.4973
`Deborah.Fishman@arnoldporter.com
`www.arnoldporter.com | LinkedIn | Twitter
`From: Hawthorne, Eric W. <Eric.Hawthorne@USPTO.GOV>
`Sent: Wednesday, March 1, 2023 8:53 AM
`To: Fishman, Deborah <Deborah.Fishman@arnoldporter.com>; lgreen@geminilaw.com;
`raynimrod@quinnemanuel.com; Trials <Trials@USPTO.GOV>
`Cc: ychu@wsgr.com; Caine, David A. <David.Caine@arnoldporter.com>; Denuyl, David
`<David.Denuyl@arnoldporter.com>; Ho, Alice <Alice.Ho@arnoldporter.com>;
`matthewtraupman@quinnemanuel.com; landonsmith@quinnemanuel.com
`Subject: IPR20223-00532, -00533, and -00556
`
` External E-mail
`
`Counsel, the Board is inquiring as to whether Patent Owner Regeneron Pharmaceuticals Inc. intends
`to file a Preliminary Response to the Petitions in these IPRs, or if it is Patent’s Owner’s intention is to
`IPR2023-00532,
`-00533 Ex. 3001
`
`
`
`waive filings.
`
`Thank you,
`Eric W. Hawthorne
`
`Supervisory Paralegal Specialist
`Patent Trial and Appeal Board
`
`
`
`This communication may contain information that is legally privileged, confidential or exempt from disclosure. If you are not the intended
`recipient, please note that any dissemination, distribution, or copying of this communication is strictly prohibited. Anyone who receives
`this message in error should notify the sender immediately by telephone or by return e-mail and delete it from his or her computer.
`___________________________________________
`For more information about Arnold & Porter, click here:
`http://www.arnoldporter.com
`
`